These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23343639)

  • 1. Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?
    Mueller-Langer F
    Health Econ Policy Law; 2013 Apr; 8(2):185-208. PubMed ID: 23343639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.
    Sheean ME; Malikova E; Duarte D; Capovilla G; Fregonese L; Hofer MP; Magrelli A; Mariz S; Mendez-Hermida F; Nistico R; Leest T; Sipsas NV; Tsigkos S; Vitezic D; Larsson K; Sepodes B; Stoyanova-Beninska V
    Drug Discov Today; 2020 Feb; 25(2):274-291. PubMed ID: 31704277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
    Kettler HE; Modi R
    Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
    Ridley DB; Sánchez AC
    Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financing R&D for neglected diseases.
    Herrling PL
    Nat Rev Drug Discov; 2009 Feb; 8(2):91. PubMed ID: 19189425
    [No Abstract]   [Full Text] [Related]  

  • 7. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solutions to the R&D crisis for neglected diseases.
    Lancet; 2008 Nov; 372(9652):1784. PubMed ID: 19027471
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing 15 proposals for promoting innovation and access to medicines globally.
    Hoffman SJ; So K;
    Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 12. Incentives for orphan drug research and development in the United States.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
    Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA program could boost treatments for neglected diseases.
    Traynor K
    Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
    [No Abstract]   [Full Text] [Related]  

  • 15. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 17. Commissioning for rare diseases: view from the frontline.
    Burls A; Austin D; Moore D
    BMJ; 2005 Oct; 331(7523):1019-21. PubMed ID: 16254306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.